[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,49,81,107,127,157,191,218,243,267,291,314,338,365,390,419,448,477,499,518],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637610","prospective-multicenter-screening-for-thoracic-disease-via-radiography-100637610",false,"NCT07585214","Prospective Multicenter Screening for Thoracic Disease Via Radiography","Thoracic Disease Screening Via Radiography: a Prospective Multicenter Study","PROMPT","Inclusion Criteria:\n\n* Age over 18.\n* Ability to understand and willingness to sign a written informed consent form.\n* Individuals presenting for routine health examinations or community-based screening.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating, or planning to become pregnant during the study period.\n* Physical limitations preventing stable positioning or breath-holding, or presence of metallic implants that may significantly degrade image quality.\n* Known history of advanced thoracic diseases currently under treatment (e.g., active lung cancer, end-stage pulmonary fibrosis, or congestive heart failure).\n* Individuals who have undergone chest CT or X-ray examinations within the past 3 months.",true,"ALL","18 Years",{"count":21,"type":22},300000,"ESTIMATED","5 Years","OBSERVATIONAL","This multicenter, prospective study aims to evaluate the real-world clinical utility of chest X-ray (CXR) for large-scale thoracic disease screening. Adult participants presenting for health examinations will undergo digital CXR screening, and any suspected abnormalities will be confirmed via a gold standard reference, such as a chest CT scan or clinical follow-up. The primary outcome measure is the detection rate (screening yield) of confirmed thoracic conditions. Secondary measures will assess diagnostic accuracy (sensitivity and specificity), false-positive rates, and multi-center reading consistency. By providing prospective, large-cohort evidence, this research seeks to validate the cost-effectiveness and feasibility of CXR in identifying early-stage lung, pleural, and cardiac abnormalities, ultimately guiding public health strategies and optimizing early medical intervention.",[27,28,29],"Pulmonary Diseases","Respiratory Disease","Esophageal Diseases",[15,31,32,33,34,35],"Thoracic","Screen","Radiography","Multicenter","Prospective","RECRUITING","2026-05-09",{"date":39,"type":40},"2026-05-13","ACTUAL",{"date":42,"type":22},"2026-05-01",{"date":44,"type":22},"2029-12-31",{"name":46,"class":47},"Chinese Academy of Sciences","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100571150","a-new-portable-device-for-non-invasive-ventilatory-support-100571150","NCT06716502","A New Portable Device for Non-invasive Ventilatory Support","A New Portable Device for PRE-hospital Non-invasive VENTilatory Support in Acute Respiratory Failure","PREVENT","Arm 1\n\nInclusion Criteria:\n\n1. Age ≥65 years\n2. Clinically stable: non-hospitalized and not in acute illness\n3. no professional medical knowledge: no experience as a health care provider\n4. Ability to express informed consent as requested by the ethical committee\n\nArm 1 Exclusion Criteria: none\n\nArm 2\n\nInclusion Criteria:\n\n1. Hospitalized adult patient\n2. SpO2 of 90-93% in room air\n\nArm 2\n\nExclusion Criteria:\n\n1. Facial burns\u002Ftrauma\u002Frecent facial or upper airway surgery\n2. Vomiting\n3. Fixed upper airway obstruction\n4. Undrained pneumothorax\n5. Recent upper gastrointestinal surgery\n6. Inability to protect the airway\n7. Bowel obstruction\n8. Patient refusal","65 Years",{"count":59,"type":22},50,"INTERVENTIONAL",[62],"NA","Acute respiratory failure is a medical emergency rapidly leading to death, if not timely treated. Prompt Continuous Positive Airway Pressure (CPAP) improves patient outcomes. However, pre-hospital CPAP is currently limited to healthcare providers due to the absence of easy-to-use and immediate devices specifically designed for the non-medical population.\n\nThe efficacy and usability of a new portable CPAP device will be assessed. This device is specifically designed for potential use in out-of-hospital scenarios involving acute respiratory failure. The evaluation will focus not only on the performance of the device but also on its easiness of use.",[65,28],"Healthy",[67,68,69],"CPAP","NIV","Respiratory failure","2026-05-05",{"date":72,"type":40},"2026-05-06",{"date":74,"type":40},"2025-09-17",{"date":76,"type":22},"2026-06-19",{"name":78,"class":79},"Università Vita-Salute San Raffaele","OTHER",3,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":18,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":48},"100577330","symptoms-respiratory-dysfunction-and-frailty-level-in-allergic-and-eosonophilic-asthmatics-100577330","NCT06796894","Symptoms, Respiratory Dysfunction and Frailty Level in Allergic and Eosonophilic Asthmatics","Comparison of Symptoms, Respiratory Dysfunction and Frailty Level in Allergic and Eosonophilic Asthmatics","Inclusion Criteria:\n\n* Age between 35-75 years,\n* Diagnosed with allergic or eosonophilic asthma according to the Global Strategy for the Prevention and Treatment of Asthma (GINA).\n\nExclusion Criteria:\n\n* Known cognitive impairment,\n* Having had an acute asthma attack in the last 6 weeks,\n* Having changed medication in the last 4 weeks.","35 Years","75 Years",{"count":91,"type":22},60,"The aim of this study is to determine the level of respiratory dysfunction, symptoms and frailty in patients with asthma according to different endophenotypes (allergic and eosonophilic asthma). In the light of the data obtained, it is thought that rehabilitation approaches that can be determined according to different endophenotypes in line with the evaluated parameters will guide health professionals working in this field.\n\nHypotheses H0: There is no difference between allergic and eosonophilic asthmatics in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life.\n\nH1: There is a difference between individuals with allergic and eosonophilic asthma in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life.",[94,28,95],"Asthma","Fragility",[94,97,95],"Respiratory Dysfunction","2025-12-25",{"date":100,"type":40},"2025-12-29",{"date":102,"type":40},"2024-08-01",{"date":104,"type":22},"2026-12-01",{"name":106,"class":79},"Hacettepe University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":18,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":48},"100605890","procedural-skills-transfer-in-bronchoscopy-100605890","NCT07168408","Procedural Skills Transfer in Bronchoscopy","Inclusion Criteria Group 1\n\n* over 16 years of age\n* patients identified as requiring a bronchoscopy by their clinician\n* patients must have had a CT scan in the 8 weeks prior to the procedure\n* capacity to consent\n\nExclusion Criteria Group 1 - Patients who have not had a CT scan in the 8 weeks prior to the procedure\n\nInclusion Criteria Group 2\n\n\\- Suitably qualified bronchoscopists, this may include trainee bronchoscopists\n\nExclusion Criteria Group 2\n\n* Clinicians who do not give consent to participate in the study\n* Clinicians who are not comfortable performing bronchoscopy while wearing the lightweight glove","16 Years",{"count":115,"type":22},320,"Brief summary The goal of this Feasibility study is to capture bronchoscopy data from patients (Group1) and bronchoscopists (Group 2) over a period of three years. The investigators wish to collect the pre-procedure CT scans and endoscopy videos of 300 patients. Up to 20 bronchoscopists will take part in the study\n\nPrimary outcomes\n\n1. To collect imaging data from patients undergoing routine bronchoscopy procedures\n2. To collect movement data from clinicians performing the routine bronchoscopy procedures using a sensory Glove\n\nSecondary outcomes\n\n1. Integrate the data gathered with procedure guidelines to develop a representation of procedure success using machine learning algorithms.\n2. Develop an actionable knowledge base for bronchoscopy skill transfer to novice\u002Funtrained medical staff.\n3. Investigate the feasibility of developing models of bronchoscopy procedures to develop training tools in the future\n\nThere are no additional samples or time commitments from the participants in Group 1.\n\nThe participants in Group 2 will be asked to answer a short questionnaire about their experience in performing bronchoscopies and will be asked to wear a sensory glove during the bronchoscopy procedure to capture their hand movements.",[28],"2025-09-09",{"date":120,"type":40},"2025-09-11",{"date":122,"type":40},"2025-05-06",{"date":124,"type":22},"2026-12",{"name":126,"class":79},"University of Edinburgh",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":60,"phases":137,"briefSummary":138,"conditions":139,"keywords":144,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":48},"100554125","how-omt-benefits-newly-diagnosed-patients-with-respiratory-illness-when-given-alongside-other-standard-care-100554125","NCT06495021","How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.","OMT and Respiratory Illness","Inclusion Criteria:\n\n* Patients being seen for respiratory illness symptoms at Geisinger 65-Forward Buckhorn, PA clinic for care.\n* Patients age of 65-100\n* New diagnosis of upper respiratory illness, sinusitis, bronchitis, or pneumonia during outpatient visit.\n\nExclusion Criteria:\n\n* Patients that have a healing fracture, including the spine, pelvis, shoulder, ribs, vertebrae, or extremities.\n* Patients actively receiving any type of cancer treatment\n* Patients with active or previously diagnosed liver disease.","100 Years",{"count":136,"type":22},68,[62],"This study is to see Osteopathic Manipulative Therapy, or OMT, can aid in treating patients being seen for respiratory illness and associated symptoms. The hypothesis is that the addition of OMT therapy, alongside other standard care (such as a medication), can help lessen patient symptoms sooner than just other treatment alone, and the duration of the condition will shorten as well.",[140,141,142,28,143],"Pneumonia","Sinusitis","Bronchitis","Respiratory Tract Infections",[145,146,147],"Osteopathic Manual Therapy","Respiratory Illness","OMT","2025-07-07",{"date":150,"type":40},"2025-07-08",{"date":152,"type":40},"2024-12-31",{"date":154,"type":22},"2026-06",{"name":156,"class":79},"Geisinger Clinic",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":18,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":60,"phases":169,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":190},"100518101","phase-2-caffeine-as-an-adjuvant-therapy-for-late-preterm-infants-with-respiratory-distress-100518101","NCT06026163","Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress","Caffeine for Late Preterm Infants: A Double Blind Randomized Controlled Trial","CAT\u002FLPT","Inclusion Criteria:\n\n* Newborn infants at gestational age 34 0\u002F7 through 36 6\u002F7\n* Presented with respiratory distress\n* Require respiratory support in the form of any of the following :\n\nA) Invasive mechanical ventilation, B) Non-invasive positive pressure ventilation, C) Nasal cannula with FIO2 requirement over 50% to keep pre-ductal saturation between 90-95%.\n\nExclusion Criteria:\n\n1 - Late preterm admitted for non-respiratory etiologies 2- Late preterm infants requiring nasal cannula on less than 50% FIO2 by 4 hours of age as they are less likely to require respiratory support for a long time.\n\n3- Newborn infants with congenital malformations and chromosomal anomalies. 4- Infants with echocardiographic evidence of PPHN requiring medical intervention.\n\n5- Late preterm with history of maternal substance abuse","1 Day","3 Days",{"count":168,"type":22},134,[170,171],"PHASE2","PHASE3","Use of caffeine citrate in late-preterm infants with respiratory distress is questionable. Oliphant and colleagues found in a recently published study that caffeine therapy use in late-preterm infants at a loading dose of 20 and 40 mg\u002Fkg and maintenance dose of 10 and 20 mg\u002Fkg\u002Fday reduces the incidence of intermittent hypoxia events by 61 and 67% respectively.\n\nThe investigators hypothesized that caffeine will improve respiratory drive, prevent apnea, shorten the hospital stay and improve arousal state in late preterm infants.\n\nThe investigators aim to study the effect of caffeine citrate on late preterm babies as regard duration of respiratory support, duration of hospital stay, respiratory morbidity, incidence and frequency of apnea.",[174,28,175],"Prematurity","Ventilator Lung; Newborn",[177,178,179,180],"caffeine","preterm","newborn","respiratory support","2025-06-24",{"date":183,"type":40},"2025-06-27",{"date":185,"type":40},"2023-10-12",{"date":187,"type":22},"2028-01-01",{"name":189,"class":47},"Ministry of Health, Saudi Arabia",2,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":190},"100499195","prospective-observational-study-to-characterize-patients-treated-at-internal-medicine-clinics-100499195","NCT05780099","Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics","MED-Cli","Inclusion Criteria:\n\n* Receving treatment at internal medicine departments (inpatient, outopatient, day hospital) of San Raffaele Hospital\n* at least one suspected or confirmed diagnosis among:\n\n  1. immune mediated disorder\n  2. respiratory disorder\n  3. metabolic disorder\n  4. sepsis\n  5. rare disorder (according to Italian Ministry of Health list)\n  6. pregnancy-related disorder\n  7. frailty defined as: either ≥2 CIRS (Cumulative Illness Rating Scale) Severity Index 10 or ≤70% Karnofsky scale\n\nExclusion Criteria:\n\n* refusal to participate\n* enrolment in other intervantional study",{"count":199,"type":22},50000,"Patients referred to internal medicine wards are becoming increasingly complex and fragile. Despite deep knowledge of their specific disorders, steps are required to improve overall management of their acute and chronic conditions. The main objective of the study is to identify demographic, clinical, laboratory and radiological markers of disease severity and activity in patients with diseases treated at general medicine wards (respiratory disease, immune-mediated disease, sepsis, metabolic disease, rare disease, frailty, pregnancy pathology) in order to improve their diagnosis, monitoring and treatment processes.",[28,202,203,204,205,206,207,208],"Cardiovascular Diseases","Infectious Disease","Critical Illness","Immunological Disease","Pregnancy Disease","Metabolic Syndrome","Chronic Disease","2025-06-17",{"date":211,"type":40},"2025-06-22",{"date":213,"type":40},"2022-06-24",{"date":215,"type":22},"2032-09-10",{"name":217,"class":79},"IRCCS San Raffaele",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":18,"minAge":225,"maxAge":23,"enrollmentInfo":226,"targetDuration":4,"studyType":60,"phases":228,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":241,"locationsCount":4},"100587309","phase-4-the-effect-of-vitamin-e-supplementation-on-hospital-stay-duration-in-non-cyanotic-heart-disease-children-with-lower-respiratory-tract-infections-100587309","NCT06926712","The Effect of Vitamin E Supplementation on Hospital Stay Duration in Non-cyanotic Heart Disease Children With Lower Respiratory Tract Infections","The Effect of Vitamin E Supplementation on Hospital Stay Duration in Non-cyanotic Heart Disease Children With Lower Respiratory Tract Infections - Randomized Controlled Trial","Inclusion Criteria:\n\n* Pediatric patients are diagnosed with non-cyanotic heart disease associated with severe lower respiratory tract infection. ⁃ The patients are aged 2 months to 5 years of both sexes.\n\nExclusion Criteria:\n\n* Pediatric patients that have other congenital anomalies other than CHD.\n\n  * Those with chronic respiratory diseases such as asthma, bronchiectasis, etc.).\n  * Immunocompromised patients, such as those who receive steroids or chemotherapy, etc.\n  * Pediatric patient that received vitamin E in the previous month.","2 Months",{"count":227,"type":22},260,[229],"PHASE4","Congenital heart disease can lead to serious health issues, particularly an increased risk of infections, specifically respiratory infections. Lower respiratory tract infections are the fifth leading cause of death globally. Also considered a significant cause of morbidity and mortality among children with congenital heart disease.\n\nIn Egypt, it is estimated that 10% of deaths in children under the age of 5 years are probably caused by lower respiratory tract infections and other acute respiratory infections. common non-cyanotic CHD like Ventricular septal defect predispose to bronchopneumonia.\n\nHemodynamically significant congenital heart disease with pulmonary congestion increases the risk of lower respiratory tract infections and hospitalizations. This relies on several modifiable risk factors, including low socioeconomic status, poor diet, overcrowding, prematurity, male gender, and exposure to secondhand smoke.\n\nMicronutrients play a crucial role in strengthening the immune system. Many Studies have shown that when children are supplemented with various micronutrients, they experience fewer episodes of acute respiratory infections, and the duration and severity of these infections are reduced.\n\nVitamin E is essential for immune system function and may lower disease risk by enhancing immune responses. It protects neurons and respiratory mucosa from oxidative damage and has been linked to a reduced incidence of asthma and inflammation, potentially safeguarding young children from atopy and wheezing.\n\nThere are no available studies in our locality about the effect of vitamin E supplementation on the length of hospital stay for non-cyanotic cardiac patients with lower respiratory tract infections.",[28],[233],"RTI-VIT E- CHD","NOT_YET_RECRUITING","2025-04-11",{"date":237,"type":40},"2025-04-15",{"date":239,"type":22},"2025-06",{"date":154,"type":22},{"name":242,"class":79},"Assiut University",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":263,"leadSponsor":265,"locationsCount":48},"100586891","development-of-the-drug-and-alcohol-respiratory-health-test-100586891","NCT06921278","Development of the Drug and Alcohol Respiratory Health Test","Psychometric Development of the Alcohol and Drug Respiratory Health Questionnaire and Evaluation of a Lung Health Clinic","DARHT","Inclusion Criteria:\n\n1. \\>18 (no upper age limit)\n2. Inhalation (smoking) of tobacco, or cannabis, or cocaine, or opioids, or use of alcohol in the past 28 days\n3. Possession of a personal mobile phone to arrange follow-up appointments\n\nExclusion Criteria:\n\n1. Reported physical health condition that would mean spirometry contra-indicated - including heart attack, unstable angina, pulmonary embolism,\n2. Reported surgery in the past 3 months for an eye, chest, or abdominal condition that would mean spirometry contra-indicated\n3. Likely inability to complete study due to criminal justice involvement with legal proceedings risking incarceration",{"count":227,"type":22},"The goal of this study is to develop a brief Drug and Alcohol Respiratory Health Test (DARHT) and offer it for routine use in clinical assessment and medical reviews",[28,254,255,94,256,257,142,140,258],"Substance-Related Disorders","COPD","Lung Cancer","Tuberculosis","Obstructive Sleep Apnea","2025-04-03",{"date":261,"type":40},"2025-04-10",{"date":237,"type":22},{"date":264,"type":22},"2025-11-11",{"name":266,"class":79},"King's College London",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":18,"minAge":274,"maxAge":166,"enrollmentInfo":275,"targetDuration":4,"studyType":60,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":48},"100516149","frequent-standardized-oral-care-using-human-milk-in-the-neonatal-intensive-care-unit-100516149","NCT06000761","Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit","Frequent Standardized Oral Care Using Human Milk to Prevent Oral Dysbiosis and Improve Health Outcomes in Premature Infants in the Neonatal Intensive Care Unit","Inclusion:\n\n* Mother ≥18 years of age\n* ≤ 30 weeks gestation\n* Born weighing ≤ 1500 grams\n\nExclusion:\n\n* Congenital anomalies of the face, lungs, or gastrointestinal system\n* Not expected to live \\> 7 days following delivery.","1 Hour",{"count":276,"type":22},218,[62],"Premature infants are susceptible to complications related to infrequent and non-standardized oral care. Although the benefits of frequent standardized oral care are known to reduce oral dysbiosis (increased level of potentially pathogenic bacteria) and its associated complications in critically ill adults leading to established evidence-based guidelines, no such information exists for VLBW infants. The proposed study will prospectively follow 168 VLBW infants for 4 weeks following birth.",[280,281,28],"Ventilator Associated Pneumonia","Bronchopulmonary Dysplasia","2025-03-31",{"date":284,"type":40},"2025-04-01",{"date":286,"type":40},"2023-11-23",{"date":288,"type":22},"2026-12-20",{"name":290,"class":79},"University of Florida",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":298,"enrollmentInfo":299,"targetDuration":301,"studyType":24,"phases":4,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":48},"100571897","extremely-preterm-respiratory-outcome-cohort-100571897","NCT06726226","Extremely Preterm Respiratory Outcome Cohort","Multicenter Cohort for Respiratory Outcome of Preterm Infants","Inclusion Criteria:\n\n* Infants born at gestational age less than 29 weeks with cohort consent obtained within 7 days of birth\n\nExclusion Criteria:\n\n* death within 3 days of birth\n* severe structural heart defects\n* structural abnormalities in the upper airway, lungs, or chest\n* congenital anomalies that may impact cardiopulmonary function\n* follow-up is difficult until 24 months of age","7 Days",{"count":300,"type":22},600,"6 Years","This study examines the respiratory outcomes of preterm infants born at gestational ages less than 29 weeks, spanning from birth to 24 months corrected age. It delves into the intricacies of respiratory function impairment attributable to diverse factors, such as respiratory distress syndrome, bronchopulmonary dysplasia, postnatal corticosteroids, ventilatory support, as well as nutritional aspect during NICU stay. Furthermore, it scrutinizes the incidence of chronic respiratory diseases stemming from these conditions, assessing their long-term impact on respiratory prognosis post-discharge. In addition to respiratory aspects, the research extends its focus to the growth and developmental outcomes of preterm infants. By synthesizing these multifaceted elements, the study aspires to enhance current treatments and preventative measures for respiratory conditions in preterm infants.",[304,28],"Infant, Premature","2024-12-04",{"date":307,"type":40},"2024-12-10",{"date":309,"type":40},"2022-06-01",{"date":311,"type":22},"2030-02-28",{"name":313,"class":79},"Seoul National University Hospital",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":337},"100458167","revive-frailty-rehabilitation-and-outcomes-in-critically-ill-adult-and-pediatric-survivors-of-covid-19-or-ari-100458167","NCT05246098","REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI","REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or Acute Respiratory Infection","REVIVe","Inclusion Criteria:\n\n* Adult and pediatric survivors of COVID-19 or acute respiratory infection admitted to participating intensive care units (ICUs) and PICUs. The investigators define children as less than, and adults as greater than or equal to, 18 years old, respectively. The investigators will include adults and pediatrics with a confirmed diagnosis of COVID-19, pediatric patients with MIS-C, and adults and pediatrics with suspected or proven acute respiratory infection with onset within 14 days of ICU\u002FPICU admission and requiring invasive mechanical ventilation, non-invasive ventilation, or high flow oxygen therapy.\n\nExclusion Criteria:\n\n* Patients who were admitted to ICU for \\\u003C24 hours",{"count":323,"type":22},900,"Background: Many adults and some children with COVID-19 or acute respiratory infection become critically ill and need advanced life support in the Intensive Care Unit (ICU). Frailty is a medical condition of reduced function and health. Adults with frailty have a lower chance of surviving critical illness. The investigators are still learning about critically ill adults with COVID-19 or acute respiratory infection, and do not have much information on how frailty affects outcomes in critically ill children, with or without COVID-19 or acute respiratory infection. Rehabilitation can help survivors of COVID-19 or acute respiratory infection by improving strength and improve quality of life (QOL).\n\nObjectives: The main goal of this research study is to see if patients with frailty have a lower chance of surviving COVID-19 or acute respiratory infection critical illness and more health problems after survival than patients without frailty. The investigators will also study the types of rehabilitation received by patients with COVID-19 or acute respiratory infection.\n\nMethods: The investigators will include adults and children with COVID-19 or acute respiratory infection who are admitted to the ICUs that participate in the study. The investigators will gather data about each patient, including before and during their illness.\n\nOutcomes: The investigators will collect level of frailty, function, and types of therapy, or rehabilitation received by patients. In adults, the investigators are most interested in learning if frailty influences mortality, or death. In children, the investigators are most interested in whether children with COVID-19 or acute respiratory infection critical illness are more likely to develop frailty. The investigators will also study post-hospital discharge location in survivors (e.g., home, rehabilitation).\n\nRelevance: The COVID-19 pandemic is a global public health crisis. It is critical to understand how COVID-19 and other acute respiratory infection critical illness affects groups of people who are at higher risk, and the impact on outcomes that are important to patients, like functioning and QOL. The results will help policy makers plan post-hospital services for survivors, help healthcare workers understand the importance of rehabilitation practice for patients with COVID-19 or acute respiratory infection, and help researchers develop treatments to improve QOL after COVID-19 or acute respiratory infection.",[28,326,327],"COVID-19","Viral Infection","2024-11-04",{"date":330,"type":40},"2024-11-06",{"date":332,"type":40},"2022-08-24",{"date":334,"type":22},"2025-10-01",{"name":336,"class":79},"McMaster University",28,{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":345,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":48},"100567825","inspire-respiratory-health-program-in-botucatu-so-paulo-brazil-100567825","NCT06673225","INSPIRE Respiratory Health Program in Botucatu, São Paulo, Brazil","Evaluation of the Implementation of the INSPIRE Respiratory Health Program: Integration of Early Diagnosis and Emergency Response for Respiratory Diseases in the City of Botucatu, São Paulo, Brazil","Inclusion Criteria:\n\n* Age equal to or greater than 18 years old;\n* Respiratory symptoms\n* History of active or passive smoking\n* Signing of informed consent form\n\nExclusion Criteria:\n\n* Difficulty understanding the issues addressed\n* Inability to contact by phone\n* Non-signing or withdrawal of informed consent",{"count":346,"type":22},2000,"The goal of this observational study is to evaluate the implementation of the INSPIRE program and to plan actions for the preparation, coordination, monitoring, diagnosis, and treatment of respiratory diseases in the municipality of Botucatu. Methods: Individuals with respiratory symptoms from the municipality of Botucatu, aged 18 or older, will be invited to participate in the study, and socioeconomic data, as well as information on sex, gender, race, nutritional risk, frailty, tobacco exposure, and its derivatives, will be collected. For those with exposure, screening and treatment for respiratory diseases will be offered through assessment of pulmonary function, body composition, respiratory and peripheral muscle strength. Additionally, individuals over 40 years old with tobacco exposure equal to or greater than 30 pack-years will be offered low-dose chest CT screening for lung cancer. Expected results: To identify and assess vulnerable groups that face difficulties in accessing respiratory healthcare, as well as implement specific strategies for the treatment of respiratory diseases and tobacco control for these groups. To ensure equitable access to respiratory health for the entire population at risk due to smoking. Moreover, through proactive and reactive risk reduction actions implemented by the program, to intervene in distinct groups and other regions.",[349,28,350],"Community Health Services","Tobacco Smoking",[352,353,354,355,356],"Primary care","Health promotion","Pulmonary function tests","Nicotine addiction","Smoking cessation","2024-10-31",{"date":328,"type":40},{"date":360,"type":40},"2024-04-16",{"date":362,"type":22},"2029-12-01",{"name":364,"class":79},"UPECLIN HC FM Botucatu Unesp",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":60,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":48},"100559884","sleepiz-one-vs-capnography-and-electrocardiography-100559884","NCT06569940","Sleepiz One+ vs. Capnography and Electrocardiography","Single-center Evaluation of Sleepiz One+ Algorithm in Estimating Respiration Rate and Heart Rate Compared to Gold Standard","Inclusion Criteria:\n\nPatients:\n\n* Age \\>=18years\n* Informed Consent as documented by signature\n* One (or more) chronic medical condition\u002Fs (e.g., diabetes, asthma, cardiovascular or respiratory diseases, etc.)\n\nHealthy volunteers\n\n* Age \\>=18years\n* Informed Consent as documented by signature\n* No diagnosed chronic medical condition\n\nExclusion Criteria:\n\nPatients\n\n* Previous enrolment into the current study,\n* Cardiac pacemaker or another implanted electrical device\n* Women who are pregnant or breastfeeding\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, delirium etc. of the participant\n\nHealthy volunteers:\n\n* Previous enrolment into the current study,\n* Cardiac pacemaker or another implanted electrical device\n* Women who are pregnant or breastfeeding\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, delirium etc. of the participant\n* Presence of diagnosed chronic medical condition",{"count":373,"type":22},35,[62],"Respiratory Rate (RR) and heart rate (HR) are vital signs crucial for assessing a patient's overall health, providing insights into various conditions and stressors. Effective management of chronic diseases relies on detecting pathological changes early, with RR being among the most sensitive predictors of patient deterioration. Therefore, vigilant monitoring of RR and HR is vital for improving patient outcomes.\n\nThe primary aim of this study is to provide a thorough comparison of the performance of Sleepiz One+ algorithms and end-tidal carbon dioxide measurement (EtCO2) Capnography for measuring respiration rate and electrocardiography (ECG) for measuring heart rate, in healthy adults and patients suffering from chronic conditions (e.g., hypertension, Chronic Obstructive Pulmonary Disease (COPD), asthma, diabetes), at rest in a clinical setting when the data is acquired with the new hardware version. Additionally, the investigators will evaluate the performance of RR estimation against the thoracic effort belt and the HR against the pulse oximetry.",[377,94,255,378,379,28,202],"Sleep Apnea","Hypertension","Diabetes","2024-08-23",{"date":382,"type":40},"2024-08-26",{"date":384,"type":40},"2024-07-18",{"date":386,"type":22},"2024-09-30",{"name":388,"class":389},"Sleepiz AG","INDUSTRY",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":17,"sex":18,"minAge":396,"maxAge":113,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":399,"conditions":400,"keywords":405,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":48},"100536929","the-gut-lung-axis-and-respiratory-illness-in-children-100536929","NCT06271213","The Gut-Lung Axis and Respiratory Illness in Children","Inclusion Criteria:\n\n* Any infant\u002Fchild\u002Fyoung person admitted to the RHC, Glasgow for an elective bronchoscopy or GI endoscopy.\n* Any infant\u002Fchild attending for an emergency\u002Felective orthopaedic operation without active respiratory or gastrointestinal conditions or receiving treatment for either condition. (Age range birth to 16 years for all groups recruited).\n* Any child attending respiratory department at RHC who can induce sputum and is having a blood sample taken, with latter part of standard of care.\n* Any infant\u002Fchild\u002Fyoung person admitted to RHC for a clinical care appointment with Asthma\u002Fwheeze before commencement of biologics therapy (treatment group).\n* Any child admitted to RHC with asthma\u002Fwheeze not indicated for biologic therapy (asthma control group).\n\nExclusion Criteria:\n\n* Use of antibiotics by the day of admission or have used antibiotics in the previous month (unless prophylactic antibiotics \\> 1 month use).\n* Any person 17 years old and above.\n* Any child known to be infected with, or at high risk of having had exposure to HIV, hepatitis B or hepatitis C viruses\n* . Any child and\u002For parent\u002Fguardian who cannot understand the English language where consent would be unethical.\n* Any child with Asthma currently receiving Biologics therapy (unless recruited via bronchoscopy route).","0 Years",{"count":398,"type":22},150,"The goal of this single-centre observational study conducted at the Royal Hospital for Children in Glasgow, Scotland, is to employ a multi-omics approach to investigate the \"gut-lung axis\" in health and disease.\n\nPart A is a cross-sectional study design investigating the postulated bidirectional link between the gut and lung microbiomes in children suffering from respiratory or gastrointestinal conditions. Children with no GI or respiratory issues attending for orthopaedic care will be used as a benchmark for a healthy gut-lung axis. The main questions we aim to answer are:\n\n* What does a healthy gut-lung axis look like?\n* Do children with respiratory issues show an altered gut microbiome?\n* Do children with GI issues show an altered lung microbiome?\n\nPart B is a longitudinal study design, that aims to assess the effects of biologics on the gut-lung axis by comparing the gut and lung microbiomes in children with asthma at two time-points who are indicated to start biologics therapy (Asthma treatment) or will not receive biologics therapy (asthma control).\n\nParticipants will provide:\n\n* airway samples (to investigate the lung microbiome)\n* blood samples (to assess inflammatory and metabolic factors which may mediate communication between the two sites) whilst under general anaesthetic for a treatment related to their standard of care\n* stool samples (to assess gut microbiome)\n* dietary information (food diary and\u002For food frequency questionnaire) to assess relationships between diet and the gut-lung axis.",[401,28,402,403,404,65],"Respiration Disorders","Asthma in Children","Wheezing","Gastro-Intestinal Disorder",[406,407,408,409],"Gut-Lung Axis","Microbiome","Multi-omics","Children","2024-02-14",{"date":412,"type":40},"2024-02-21",{"date":414,"type":40},"2024-02-04",{"date":416,"type":22},"2028-05-01",{"name":418,"class":79},"NHS Greater Glasgow and Clyde",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":447},"100533565","a-clinical-study-to-map-the-hla-genomic-region-in-the-greek-population-100533565","NCT06227468","A Clinical Study to Map the HLA Genomic Region in the Greek Population","A Clinical Study to Map the HLA GENomic Region and Its potEntial aSsocIation With Selected diSeases in the Greek Population","GENESIS","Inclusion Criteria:\n\nThe study will include adult subjects (age ≥ 18) that:\n\n* possess a Greek social security number and are visiting hospitals\u002Fclinics, and\u002For other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,\n* are willing and able to provide written informed consent to participate in the study according to the study protocol.\n\nExclusion Criteria:\n\n* Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).\n* Subjects who have had an allogeneic (non-self-donor):\n\n  * bone marrow transplant\n  * stem cell transplant\n  * blood transfusion less than two weeks prior to buccal swab sample collection\n  * liver transplant\n* Subjects who participated in an interventional clinical trial in the past that according to the subject's physician opinion might have had an impact on their HLA genome.",{"count":428,"type":22},12000,"The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.",[65,28,431,202,432,433,434,435,436,437],"Chronic Renal Failure","Metabolic Disease","Psychiatric Disorder","Neurologic Disorder","Gastrointestinal Diseases","Haematologic Disease","Rheumatologic Disease","2024-01-25",{"date":440,"type":40},"2024-01-26",{"date":442,"type":40},"2023-12-12",{"date":444,"type":22},"2026-08-31",{"name":446,"class":79},"Athens LifeTech Park",8,{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":18,"minAge":165,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":60,"phases":458,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":4},"100508613","isotonic-saline-for-children-with-bronchiolitis-100508613","NCT05902702","Isotonic Saline for Children With Bronchiolitis","Isotonic Saline for Children With Bronchiolitis - a Randomized Controlled Non-inferiority Trial","Inclusion Criteria:\n\n* Children aged 0-12 months, whose parents give informed consent to participate, with symptoms of bronchiolitis including at least one of:\n\n  * Runny nose\n  * Dry and persistent cough\n  * Labored breathing (tachypnea, retractions, nasal flaring)\n  * Grunting\n  * Cyanosis or apnea\n  * Wheezing or crackles on auscultation\n  * O2 saturations below 92 %\n  * Difficulties feeding\n\nExclusion Criteria:\n\n* Children with cystic fibrosis or other serious congenital lung diseases\n* Children in whom treatment with short-acting beta-2 agonist is initiated (as this is delivered in nebulized isotonic saline).","12 Months",{"count":457,"type":22},300,[62],"The goal of this randomized clinical trial is to investigate the optimal supportive treatment of bronchiolitis in infants from 0-12 months of age. The main question\\[s\\] it aims to answer are:\n\n* To investigate whether isotonic saline should be used as supportive treatment for children with bronchiolitis, and if so, identify the optimal route of administration. The primary outcome is duration of hospitalization.\n* To investigate the current epidemiology of the viral pathogens causing bronchitis in children in Denmark, and to assess whether children infected with specific pathogens might benefit from treatment with isotonic saline.\n\nThe children are randomized after inclusion through computer randomization to one of the 3 arms in the study:\n\n1. Nebulized isotonic saline\n2. Nasal irrigation with isotonic saline\n3. No treatment with saline\n\nThe investigators will compare treatment with saline (both methods) with no treatment, and the investigators will also compare the two methods of delivery of saline (nebulized vs. nasal irrigation).",[461,28,402,327,462],"Bronchiolitis","Acute Respiratory Infection",[464,465,466,467],"Nebulized saline","Nasal saline drops","Nasal saline irrigation","Respiratory severity score","2023-06-13",{"date":470,"type":40},"2023-06-15",{"date":472,"type":22},"2023-09",{"date":474,"type":22},"2029-09",{"name":476,"class":79},"Slagelse Hospital",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":18,"minAge":396,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":48},"100477793","measures-of-respiratory-health-registry-100477793","NCT05501587","Measures of Respiratory Health Registry","MRH","Participants with CF\n\nInclusion Criteria:\n\n-Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria: i. A documented sweat chloride ≥ 60 mEq\u002FL by quantitative pilocarpine iontophoresis (QPIT).\n\nii. A documented genotype with two disease-causing mutations in the CFTR gene.\n\n\\- In the opinion of the investigator, the participant will likely have the ability to perform the lung function test of interest on the day of testing\n\nExclusion Criteria:\n\n* Physical findings at the screening that would compromise the safety of the participant or the quality of the data (e.g. respiratory distress or work of breathing)\n* Requirement of supplementary oxygen to maintain oxygen saturation above 95%\n\nParticipants with other Respiratory Disease\n\nInclusion criteria:\n\n* Physician-diagnosed lung disease\n* Informed consent by participant, parent, or legal guardian\n* In the opinion of the investigator, the participant will likely have the ability to perform the lung function test of interest on the day of testing\n\nExclusion criteria\n\n* Physical findings at screening that would compromise the safety of the participant or the quality of the research data\n* Requirement of supplementary oxygen to maintain oxygen saturation above 95%\n\nHealthy Participants\n\n* Inclusion criteria\n* Informed consent by participant, parent, or legal guardian\n* In the opinion of the investigator, the participant will likely have the ability to perform the lung function test of interest on the day of testing\n\nExclusion criteria\n\n* Physical findings at screening that would compromise the safety of the participant or the quality of the research data\n* Evidence of lung disease","99 Years",{"count":486,"type":22},1000,"There are many techniques that can allow for the quantification of lung function in children; some are being used clinically and others are under development. Many of these tools are available at BC Children's Hospital. This registry study will act as a central repository for the results of traditional and novel pulmonary function tests done at BC Children's Hospital to allow for future analysis.",[28,489],"Cystic Fibrosis","2022-08-11",{"date":492,"type":40},"2022-08-15",{"date":494,"type":40},"2018-10-11",{"date":496,"type":22},"2028-05",{"name":498,"class":79},"University of British Columbia",{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":17,"sex":18,"minAge":396,"maxAge":484,"enrollmentInfo":506,"targetDuration":507,"studyType":24,"phases":4,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":190},"100447160","imaging-measures-of-respiratory-health-registry-100447160","NCT05102825","Imaging Measures of Respiratory Health Registry","iMRH","Respiratory Disease\n\nInclusion Criteria:\n\n1. Physician-diagnosed lung disease - based on a diagnosis made by a treating staff physician and confirmed by the principal investigator.\n2. Age 0-99 years.\n3. Informed consent by participant, parent, or legal guardian\n4. In the opinion of the Investigator, the participant will likely be able to perform maneuvers to obtain technically acceptable pulmonary XeMRI images.\n\nExclusion Criteria:\n\n1. Physical findings at screening that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the research data.\n2. Requirement of supplementary oxygen to maintain an oxygen saturation above 95%.\n3. Failed MRI screening form.\n4. History of claustrophobia.\n5. Known current pregnancy or lactation.\n\nHealthy\n\nInclusion Criteria:\n\n1. Age 0-99 years\n2. Informed consent by participant, parent, or legal guardian\n3. In the opinion of the Investigator, the participant will likely be able to perform maneuvers to obtain technically acceptable pulmonary MRI images.\n\nExclusion Criteria\n\n1. Physician-diagnosed lung disease.\n2. Failed MRI screening form.\n3. History of claustrophobia.\n4. Physical findings at screening that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the research data.\n5. Known current pregnancy or lactation.",{"count":486,"type":22},"10 Years","This is a prospective, observational cohort registry that aims to collect data on pulmonary structure and function in healthy people and those with respiratory disease, using structural and functional pulmonary 1H-MRI and hyperpolarized 129Xe-MRI.\n\nOutcome measures generated from MRI may include but are not limited to measures of regional ventilation, pulmonary microarchitecture, and regional gas exchange. Additionally, one of the goals of the registry is to facilitate the development of novel image analysis techniques that have not yet been invented.\n\nThese data will be stored along with demographic data, clinical data, and pulmonary function testing (PFT) data.\n\nThis is an open registry. Eligible local and international investigators\u002Finstitutions can apply for access.",[28,65],"2021-10-29",{"date":512,"type":40},"2021-11-02",{"date":514,"type":40},"2020-06-11",{"date":516,"type":22},"2045-06-01",{"name":498,"class":79},{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":17,"sex":18,"minAge":526,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":530,"conditions":531,"keywords":541,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":48},"100357508","hamburg-city-health-study---a-german-cohort-study-100357508","NCT03934957","Hamburg City Health Study - a German Cohort Study","A Single Center, Prospective, Epidemiologic Cohort Study With Emphasis on Imaging to Improve the Identification of Individuals at Risk for Major Chronic Diseases and to Improve Early Diagnosis and Survival","HCHS","Inclusion Criteria:\n\n* Inhabitant of the city of Hamburg at the time of inclusion into the study (Inclusion is time of written consent)\n* Age 45 to 74 years\n* Personally signed informed consent\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language, in order to understand study documents and computer assisted interview without translation\n* Physical or psychological incapability to travel to the study center and to cooperate in the investigations","45 Years","74 Years",{"count":529,"type":22},45000,"The Hamburg City Health Study (HCHS) is a large, prospective, long-term, population-based cohort study and a unique research platform and network to obtain substantial knowledge about several risk and prognostic factors in major chronic diseases.",[532,533,534,535,536,537,538,539,28,540],"Coronary Heart Disease","Stroke","Dementia","Cancer","Health Care","Vascular Diseases","Periodontal Diseases","Ocular Diseases","Obesity",[542,543,544,545,546],"Epidemiology","prospective cohort study","Nutrition","prevention","psychiatric and psychosomatic disorders","2019-04-28",{"date":549,"type":40},"2019-05-02",{"date":551,"type":40},"2016-02-08",{"date":553,"type":22},"2028-12-31",{"name":555,"class":79},"Universitätsklinikum Hamburg-Eppendorf"]